Announcements Trials
Browse Landscape

Phase

Phase 3 10Phase 4 8Phase NA 3Phase 2 3Phase 1 2Phase 1/2 1

Status

Completed 2Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1

Conditions

Uveal Melanoma 1Melanoma 1Healthy 1

Interventions

Paclitaxel 291Gemcitabine 254Carboplatin 253Cisplatin 250Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 180Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Ipilimumab 90Pemetrexed 89fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Completed × Adalimumab × Clear all
NCT04551352 2022-10-03

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Hoffmann-La Roche

Phase 1 Completed
20 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT02912247 2019-03-07

Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
183 enrolled

Healthy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡